Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.52 |
| ▸ | KIT | P10721 | 4/20 | 0.49 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.47 |
| ▸ | SPIN1 | Q9Y657 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 5/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20581274 | 0.87 | SPIN1 (0.59) | TLR9TLR7KITMAP2K7SPIN1 | |
| SCHEMBL2392382 | 0.87 | MAP2K7 (0.58) | KITMAP2K7PDGFRAACHEBACE1 | |
| SCHEMBL20580814 | 0.86 | SPIN1 (0.58) | TLR9TLR7KITMAP2K7SPIN1 | |
| SCHEMBL14196201 | 0.81 | KIT (0.62) | KITPDGFRAAURKA | |
| SCHEMBL13938480 | 0.81 | KIT (0.62) | KITPDGFRAAURKA | |
| SCHEMBL13962610 | 0.80 | KIT (0.61) | KITPDGFRAAURKA | |
| SCHEMBL13938479 | 0.79 | KIT (0.63) | KITPDGFRAAURKA | |
| SCHEMBL13938485 | 0.78 | KIT (0.69) | KITPDGFRAAURKA | |
| SCHEMBL13938483 | 0.78 | KIT (0.68) | KITPDGFRAAURKA | |
| SCHEMBL13938477 | 0.77 | KIT (0.60) | KITPDGFRAAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029982-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008055233-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-1888588-A2 | PROTEIN KINASE INHIBITORS | SuperGen, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006116733-A2 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | ERBB3, ERBB2, AXL | TLR9 4118/4885TLR7 4124/4885KIT 960/4885 |
| US-20090029982-A1 | PROTEIN KINASE INHIBITORS | CDK2, PACSIN2, AKT1 | TLR9 4363/4885TLR7 4380/4885KIT 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.